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Rapid activation of ERK1/2 and AKT in human breast cancer
cells by cadmium
Zhiwei Liu, Xinyuan Yu, and Zahir A Shaikh*
Department of Biomedical and Pharmaceutical Science, and Center for Molecular Toxicology,
College of Pharmacy, University of Rhode Island, Kingston, RI 02881
Abstract
Cadmium (Cd), an endocrine disruptor, can induce a variety of signaling events including the
activation of ERK1/2 and AKT. In this study, the involvement of estrogen receptors (ER) in these
events was evaluated in three human breast caner cell lines, MCF-7, MDA-MB-231, and SK-
BR-3. The Cd-induced signal activation patterns in the three cell lines mimicked those exhibited in
response to 17β-estradiol. Specifically, treatment of MCF-7 cells, that express ERα, ERβ and
GPR30, to 0.5-10 μM Cd for as little as 2.5 min resulted in transient phosphorylation of ERK1/2.
Cd also triggered a gradual increase and sustained activation of AKT during the 60 min treatment
period. In SK-BR-3 cells, that express only GPR30, Cd also caused a transient activation of
ERK1/2, but not of AKT. In contrast, in MDA-MB-231 cells that express only ERβ, Cd was
unable to cause rapid activation of either ERK1/2 or AKT. A transient phosphorylation of ERα
was also observed within 2.5 min of Cd exposure in the MCF-7 cells. While the estrogen receptor
antagonist, ICI 182,780, did not prevent the effect of Cd on these signals, specific siRNA against
hERα significantly reduced Cd-induced activation of ERK1/2 and completely blocked the
activation of AKT. It is concluded that Cd, like estradiol, can cause rapid activation of ERK1/2
and AKT and that these signaling events are mediated by possible interaction with membrane
ERα and GPR30, but not ERβ.
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Introduction
Cadmium (Cd) is a heavy metal that is widely distributed throughout the environment as a
result of pollution from a variety of sources. The environmental exposure to Cd occurs
through contaminated food and cigarette smoke. For the general population, tobacco
smoking is an important source of Cd exposure (WHO/IPCS, 1992). Cd is classified as a
category I carcinogen by the International Agency for Research on Cancer (IARC, 1993).
However, in comparison with the other carcinogenic metals, Cd is not a strong cancer
initiator and instead, it is a weak mutagen (Rossman et al., 1992). Cd-induced stimulation of
cellular signaling at various stages of the mitogenic cascade, proto-oncogene expression,
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DNA synthesis, and cell proliferation in various mammalian cell systems is thought to be the
mechanisms for the carcinogenic action of this metal.
During the last decade, a growing body of evidence has accumulated suggests that in certain
cell types micromolar concentration of Cd is able to initiate a series of rapid signaling events
including: generation of second massagers (IP3, cAMP) within 15-30 sec (Smith et al.,1989;
Yamagami et al., 1998); increase in intracellular calcium within 3 min (Smith et al.,1989;
Yamagami et al., 1998); activation of certain kinases (Hung et al., 1998; Galan et al., 2000;
Misra et al., 2002; 2003); and induction of early response genes c-fos and c-myc within 30
min (Beyersmann and Hechtenberg, 1997; Misra et al., 2002; 2003). Since these signals
were generated soon after Cd exposure, it argued against a physiological interaction between
Cd and intracellular proteins. It has been postulated that Cd might bind to and activate a
putative cell membrane receptor and trigger the downstream signaling events. However,
only a limited number of studies (Misra et al., 2002; 2003) have explored this possibility,
and there is no definitive study that elucidates the nature of the receptor that might possibly
mediate this effect.
Estrogen can modulate cellular functions through non-genomic actions which are initiated
from the cell membrane. There are two proposed models for the rapid response to estrogen
action. The first model proposes that the membrane-bound estrogen receptor alpha (mERα)
is associated with the cell membrane proteins, including G protein and receptor tyrosine
kinase, and mediates the rapid signaling induced by estrogen (Razandi et al., 2003a, b; 2004;
Pedram et al., 2006). The second model proposes that another membrane G protein-coupled
protein, GPR30 is involved in this process (Filardo et al., 2000; 2002; Norman et al., 2004;
Hewitt et al., 2005; Revankar et al., 2005; Thomas et al., 2005). Although the nature of
mERα is still debated (Song and Santen, 2006; Warner and Gustafsson 2006), there is
evidence that in certain cell types, a small fraction of ERα, that is associated with the cell
membrane and originates from the same transcript of classical ERα, is required for rapid
effects of estrogen (Razandi et al., 2003a, b; 2004; Song et al., 2004; Pedram et al., 2006).
At relatively low doses (5-10 μg/kg, ip), Cd is able to increase uterine wet weight, promote
growth and development of mammary gland, and induce hormone-regulated genes in
ovariectomized rats (Johnson et al., 2003). As a xenoestrogen, Cd has the ability to bind to
ERα with high affinity (Kd = 4.5 × 10-10), and activate and alter estrogen target gene
transcription and expression (Garcia et al., 1994; Stoica et al., 2000). If the non-genomic
effects of E2 are mediated by membrane ERα (mERα), it is conceivable that Cd may also
trigger a rapid signaling cascade by the same mechanism.
Mitogen activated protein kinases (MAPKs) are serine/threonine protein kinases that play
important roles in the signaling cascades regulating cellular process such as cell
proliferation, differentiation and apoptosis. Three major subfamilies have been described:
extracellular-regulated kinases (ERK), c-JUN N-terminal kinase (JNK), and p38 kinase.
Depending on the cellular context and stimulators, there is a significant cross talk between
transduction modules as they can respond to a common upstream activator and
phosphorylate common down stream target. In general, the ERK pathway is preferentially
activated in response to growth and differentiation factors, while JNK and p38 kinase are
more sensitive to stress stimuli including heat shock, inflammatory cytokines, ultraviolet and
gamma irradiation, and hyperosmolarity (Roux and Blenis, 2004). The cells show different
temporal and dose-response patterns to Cd treatment in terms of activation of MAPKs.
Among the three major subfamilies of MAPKs, ERK1/2 is usually activated by Cd much
earlier than JNK and p38 kinase (Alam et al., 2000; Chuang et al., 2000; Chuang and Yang,
2001; Huang et al., 2001; Iryo et al. 2000). Additionally, rapid activation of ERK1/2 is
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widely used as an endpoint to reflect E2-induced non-genomic effects in a variety of cell
types (Filardo et al., 2000; 2002; Razandi et al., 2003a, b; 2004; Pedram et al., 2006).
The activation of either ERK1/2 or AKT, or both pro-survival kinases, could prevent cells
from undergoing apoptosis induced by certain chemical or physical agents. The serine/
threonine protein kinase PI3K/AKT is also activated by various growth and survival factors.
AKT promotes cell survival through two distinct pathways: inhibition of apoptosis by
phosphorylation of the Bad component of the Bad/Bcl-XL complex, causing dissociation of
the Bad/Bcl-XL complex and allowing cell survival; and activation of IKK that ultimately
leads to NF-kB activation and cell survival (Hennessy et al., 2005). E2 can induce the
activation of AKT in endothelial cells from wild type mice within 15 min, but not in cells
from ERα/ERβ combined-deleted mice (Pedram et al., 2006). Misra et al. (2003) reported
that in 1LN prostate cells AKT was activated by 1 μM Cd within 20 min.
The present study was designed to investigate rapid signaling in response to Cd in three
human breast cancer cell lines with different expression profiles for ERα, ERβ and
GPCR30.
Materials and methods
Chemicals and biochemicals
17β-estradiol (E2) and phenol red-free DMEM/Ham’s F12 were obtained from Sigma-
Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was purchased from HyClone (Logan,
UT). The synthetic estrogen antagonist ICI 182,780 was purchased from Tocris Chemicals
(Ellisville, MO). Antibodies against phospho-ERK1/2 (Thr202/Tyr204), phospho-AKT
(Ser473), phospho-ERα (Ser118), ERK2, and AKT were purchased from Cell Signaling
Technology (Danvers, MA). The Anti-ERα (HC-20) antibody was purchased from Santa
Cruz Biotechnology (Santa Cruz, California). Blocking buffer was obtained from Li-Cor
(Lincon, NE). For siRNA studies, a smart pool of double-stranded siRNA against human
ERα (hERα; M-003401-02) and non-specific siRNA (D-001206-01-05) were obtained from
Dharmacon Tech (Lafayette, CO). The siRNA transfection reagent siPORT lipid was
purchased from Ambion (Austin, TX). All the other chemical reagents were either from
Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Suwanee, GA).
Cell culture
The three breast cancer cell lines, MCF-7 (ERα-, ERβ-, and GPR30-positive), MDA-
MB-231(ERβ-positive), and SK-BR-3 (GPR30 positive), were purchased from American
Type Culture Collection (Mannassas, VA). The cells were grown and maintained in phenol
red-free DMEM/Ham’s F12 medium (1:1) containing 1.2 g/L sodium bicarbonate, 10% FBS
and 50 mg/L gentamicin (Filardo et al., 2000; 2002). Stock cultures were maintained in the
complete medium in a humidified atmosphere of 95% air-5% CO2 at 37°C and employed for
experiments within 15 serial passages. The cells were sub-cultivated every 6-7 days using a
mixture of 0.25% trypsin and 0.03% EDTA.
Cell exposure and preparation of cell extract
The cells (1 × 105/cm2) were seeded in T-75 flasks or 6-well cell culture plates in phenol
red-free DMEM/F-12 medium containing 10% FBS. The next day, the medium was
replaced with the phenol red-free, serum-free medium and the cells were maintained for 48
h. Treatment of quiescent cells (60%-80% confluences) with Cd was carried out at 37°C in
phenol red-free, serum-free, medium as described in the figure legends. Since 10 μM Cd has
been commonly used by other researchers for studying the effects of Cd on MAPKs
(Chuang et al., 2000; Chuang and Yang 2001; Huang et al., 2001; Iryo et al. 2000), the same
Liu et al. Page 3
Toxicol Appl Pharmacol. Author manuscript; available in PMC 2012 October 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
concentration was used in the present study for comparison with the earlier reports. As
determined by the MTT and trypan blue exclusion assays, treatment of cells with 10 μM Cd
for 60 min did not cause cytotoxicity (data not show). At the end of Cd treatment, the cells
were washed twice with ice-cold phosphate-buffered saline (PBS) and lysed with ice-cold
RIPA buffer (150 mM sodium chloride, 100mM Tris, pH 7.5, 1% deoxycholatic sodium,
0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 100 mM sodium pyrophosphate, 3.5
mM NaVO4, 2 mM PMSF, 50 mM NaF, 2 mM EDTA, plus protease inhibitor cocktail at a
ratio of 1000:1). The crude cell lysates were centrifuged at 13,000g for 15 min and the
supernatants were stored at -80°C until analyzed. The protein concentration was determined
using micro BCA reagent kit from Pierce Biotechnology (Rockford, IL) according to the
manufacturer’s instructions.
Western blot analysis
Prior to electrophoresis, the cell extracts were heated at 95-100°C in Laemmli buffer
containing 5% β-mecaptoethanol for 5 min. The amount of protein in the extract used for
electrophoresis was kept constant in the same experiment but varied between the
experiments (15-30 μg). After electrophoresis, the proteins were electrotransferred to
nitrocellulose membrane at 20 V for 20 min by using Trans-Blot SD Semi-dry Transfer Cell
(Bio-Rad, Hercules, CA). The membranes were then blocked with the Li-Cor blocking
buffer for 1 h at room temperature and incubated with primary antibodies diluted in
PBS-0.1% Tween-20 containing 2.5% BSA (PBST-BSA) overnight at 4°C or for 1 h at
room temperature. The nitrocellulose membranes were washed and incubated with
secondary antibody labeled with Alexa Fluor 680 (1:15,000 diluted in blocking buffer
containing 0.1% Tween-20) for 1 h followed by extensive washing with PBS-0.1%
Tween-20. The washed membranes were scanned with the Odyssey Infrared Imager (Li-Cor,
Lincon, NE) and the optical density of the bands was quantified by using the application
software version 1.2.15.
Transfection with the small interfering RNA (siRNA)
The siRNA transfection was conducted according to the instructions provided by
Dharmacon Tech (Lafayette, CO). Briefly, the cells were transfected with either non-
specific siRNA (control) or siRNA against human ERα (hERα), and then recovered
overnight. The cells were serum-deprived for 24 h prior to treatment with Cd.
Data analysis
Each experiment was repeated three times and the optical density data were statistically
analyzed for significant differences by one-way ANOVA, followed by the Tukey-Kramer
test, at p<0.05.
Results
Activation of ERK1/2 by Cd
The presence of phosphorylated threonine and tyrosine residues in MAPK correlates with
the activities of kinases. Thus, to assess activated ERK1/2 levels, the cell extracts were
processed using Western blot analyses using antibodies against phosphorylated peptides
encompassing ERK1/2 residues. First, the time-course of Cd-induced ERK1/2 activation
was compared between the MCF-7, MDA-MB-231, and SK-BR-3 cells. E2 was used as a
positive control and response pattern comparisons were made between E2 (10 nM) and Cd
(10 μM). The effect of medium change on the ERK1/2 levels was examined in untreated
MCF-7 cells and no significant changes were observed (data not shown). As depicted in Fig.
1A, B, G, and H, the temporal response pattern of ERK1/2 activation induced by Cd in
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MCF-7 cells was similar to that induced by E2. Maximal ERK1/2 activation by both E2 and
Cd was observed at 2.5 min followed by a gradual decrease over the 60 min period. In
contrast to the MCF-7 cells, neither Cd nor E2 activated ERK1/2 in the MDA-MB-231 cells
that express only ERβ (Fig. 1C, D, G, and H). However, in the SK-BR-3 cells, that express
only GPR30, both Cd and E2 caused transient activation of ERK1/2 (Fig. 1E, F, G, and H),
similar to that observed in the MCF-7 cells. These results indicated that mERα and GPR30,
but not ERβ were important in Cd-induced rapid signaling of ERK1/2.
The concentration-response data of MCF-7 cells to 0.5-10 μM Cd are shown in Fig. 2A and
B. The cells exposed to the lowest concentration of Cd (0.5 μM) for 2.5 min showed a
significant increase (2.2-fold) in ERK1 activation. The maximum activation (6.3-fold) was
seen at the 5-10 μM Cd.
Activation of AKT by Cd
Since PI3K/AKT is activated through phosphorylation of threonine by an upstream kinase,
the activation of AKT can be detected by Western blot analysis using a phospho-specific
antibody that recognizes the peptide containing threonine residues. As with ERK1/2,
medium change had no significant effect on the AKT levels in the untreated MCF-7 cells
(data not shown). As shown in Fig. 3A and G, Cd significantly increased (3.3-fold) the
phosphorylated AKT in MCF-7 cells within 2.5 min and continued to do so (5.4-fold) for the
duration of the experiment. The E2- induced AKT activation showed a similar pattern (Fig.
3B and H). In the MDA-MB-231 cells, Cd but not E2 induced a moderate activation of AKT
only at 60 min (Fig 3C, D, G and H). In comparison, AKT phosphorylation in the SK-BR-3
cells was not affected by either Cd or E2 at any time, similar to the response of these cells to
ERK1/2 phosphorylation. Thus, these data also pointed to the involvement of mERα in
AKT signaling by Cd.
Phosphorylation of ERα by Cd
The results obtained for both ERK1/2 and AKT phosphorylation in the MCF-7 cells
suggested that mERα might play a role in Cd-induced rapid signaling. Thus, to further
delineate its involvement in Cd-induced signaling, the phosphorylation of ERα was
investigated in quiescent MCF-7 cells after treatment with Cd and E2. As shown in Fig. 4A
and C, Cd transiently elevated (3.9-fold) the level of phosphorylated receptor at 2.5 min. In
comparison, E2 caused a gradual and more sustained ERα phosphorylation (Fig. 4B).
Effect of an estrogen antagonist on Cd-induced ERK1/2 and AKT activation
Since E2-induced rapid activation of ERK1/2 in MCF-7 cells is through mERα, ICI
182,780, an estrogen antagonist, is able to antagonize both E2-induced genomic and non-
genomic rapid signaling effects. In the present study, the possible role of mERα in Cd-
induced rapid signaling was examined using the same antagonist. The quiescent MCF-7
cells were pretreated with 10 μM ICI 182,780 for 15 min, and then treated with 10 μM Cd
or 10 nM E2 for 2.5 min in the presence of the antagonist. Since ICI 182,780 stock solution
(10 mM) was prepared in ethanol, the control cells were incubated with medium containing
0.1% ethanol. As depicted in Fig. 5A-D, whereas the antagonist completed blocked the E2-
induced phosphorylation of both kinases. It had no significant effect on the Cd-induced
phosphorylation of either kinase. Lack of effect of Cd-induced activation of ERK1/2 and
AKT by the receptor antagonist was contrary to all the other results obtained thus far and
suggested an mERα-independent mechanism.
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Effect of siRNA against hERα on Cd-induced ERK1/2 activation
To further evaluate the role of mERα in Cd-induced rapid activation of ERK1/2 and AKT, a
second approach was utilized in which specific siRNA was used to knockdown the
expression of the receptor. Transfection with hERα siRNA markedly, but not completely,
suppressed the expression ERα in quiescent MCF-7 cells (Fig. 6A and B). Whereas this
level of suppression of ERα expression was sufficient to completely block the E2-induced
rapid activation of both ERK1/2 and AKT (Fig. 6A-D), it only partially blocked (60%) the
Cd-induced activation of ERK1/2 (Fig. 6A and C). However, it completely blocked the
activation of AKT (Fig. 6B and D). These results suggest that, in addition to mERα, other
receptors might also be involved in interacting with Cd.
Discussion
Cd has been described as an endocrine disrupting chemical by a number of investigators
(Takiguchi and Yoshihara, 2006; Henson and Chedrese, 2004). As a xenoestrogen, Cd can
alter the expression of certain estrogen target genes and affect breast tissue development in
ovariectomized rats (Johnson et al., 2003). Other metals, such as arsenic and uranium have
also been evaluated for the reproductive tissue effects, but Cd is the only one with
demonstrated effects on mammary proliferation (Johnson et al., 2003; Fenton, 2006).
Although there is no definitive epidemiological evidence showing a positive relationship
between Cd exposure and breast cancer incidence in the general population (Nagata et al.,
2005; McElroy et al., 2006), as a xenoestrogen, Cd may play a role in cancer promotion and
progression after the cancer is initiated (Brody and Rudel, 2003; Yager and Davidson,
2006). The mechanism by which Cd disrupts endocrine function remains poorly understood.
The results obtained in the present study demonstrated that in MCF-7 cells, a relatively
benign breast cancer cell line, Cd was able to rapidly activate ERK1/2, AKT and ERα at a
micromolar concentration within 2.5 min. Under the same exposure condition, SK-BR-3
cells, a moderately malignant breast cancer cell line, responded a bit more slowly (7.5 min)
in terms of ERK1/2 activation. In comparison, a highly invasive breast cancer cell line,
MDA-MB-231, did not show a rapid response to Cd treatment at all. From the dramatic
response differences between these three cell lines, it might be speculated that sensitivity to
Cd might be associated with the relative invasiveness of the breast cancer cells.
Since activation of both ERK1/2 and AKT plays a role in regulating various cellular
processes such as cell growth, cell differentiation, and apoptosis induced by certain chemical
or physical agents, more studies need to be performed to further elucidate how Cd-induced
rapid signaling affects the normal function of breast tissue and it’s susceptibility to certain
stresses. In the present study, Cd also induced rapid phosphorylation of ERα, which might
make the cells more sensitive to relatively low levels of E2. Although the downstream
effects were not investigated in the present study, the results of ERK1/2, AKT and ERα
phosphorylation suggest that even occasional exposure to Cd might cause transient effects
on the normal physiology of the breast tissue and might disrupt the normal homeostasis,
especially if the exposure occurs in early critical period of breast development (Fenton
2006). The potential short-term exposure to low concentration of Cd is of environmental
health importance and may have biological significance, especially when the subjects are co-
exposed to other chemicals or physical stress agents (Brody and Rudel, 2003).
The results presented in this study also showed that Cd, like E2, caused rapid
phosphorylation of ERK1/2 in MCF-7 cells only 2.5 min after treatment. This suggests that
Cd and E2 possibly share a similar downstream signal transduction pathway and regulatory
mechanism. The rapid inactivation of ERK1/2 implies the existence of a tightly controlled
regulatory mechanism. In comparison with the present study, Silva et al. (2006) reported
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that 0.1 μM Cd did not induce significant activation of ERK1/2 in MCF-7 BUS cells during
the 5-20 min treatment period. Although the differences in biological characteristics and
sensitivity to E2 and endocrine disruptors among different MCF-7 cell stocks may partially
contribute to the differences in Cd-induced rapid activation of ERK1/2 (Villalobos et al.,
1995), it is also possible that 0.1 μM Cd is too low a concentration to detect any significant
effects. In this regard, the present study provided a more comprehensive concentration-
response data about Cd-induced rapid signaling in the MCF-7 cells between 0.5 and 10 μM
concentration.
Alam et al. (2000) reported increased phosphorylation of ERK1/2 in the MCF-7 cells in
response to Cd starting at 15 min and peaking at 1 h. They used MCF-7 N variant cells
which could partly account for their results and those reported in the present study (Burow,
et al., 1998). Secondly, these investigators used DMEM containing phenol red, and
performed 24 h serum starvation before exposure. The present study utilized phenol red-free
DMEM/F-12 medium and serum starved the cells for 48 h. Because phenol-red is a weak
estrogen mimic, it can interfere with the effects of estrogen. Therefore, phenol-red should be
excluded from the medium when studying the effects of estrogen or endocrine disruptors.
Additionally, since ERK1/2 can be activated very rapidly, early time points need to be
considered in designing such studies.
Guerra et al. (2004) observed that short treatment of septal murine cells (SN56) with E2
caused a biphasic activation of ERK1/2, with peak induction at 4-8 min in the early phase
and 8 h in the second phase. Similarly, Marino et al. (2003) reported that treatment of
HepG2 cells with E2 also caused a biphasic phosphorylation of AKT with peaks at 3 and 30
min, respectively. Furthermore, that the first wave of activation was ER-independent,
whereas the second was ER-dependent.
Without serum starvation, 20 μM Cd induced significant phosphorylation of ERK1/2 in
MCF-7 cells only after 18 h of exposure (Matsuoka and Igisu, 2001). Brama et al. (2007)
also studied Cd-induced activation of ERK1/2 and AKT in the MCF-7 cells and reported
maximum activation between 3 and 6 h. They concluded that this activation occurred
through an ERα-dependent mechanism, because it could be fully blocked by ICI 182,780. In
comparison, in the present study, Cd caused rapid activation of ERK1/2 at 2.5 min in the
MCF-7 cells and while it was not blocked by ICI 182,780, it was partially blocked in cells
transfected with by hERα. Thus, Cd like E2 induces a biphasic activation of ERK1/2;
however, both phases might involve ERα.
Besides the breast cancer cells, the activation of ERK1/2 by Cd has been reported in several
other cell types, including CCRF-CEM cells, non-small-cell lung carcinoma cell line CL3,
and mouse epidermal JB6 C141 cells (Iryo et al., 2000; Chuang et al., 2000; Chuang and
Yang, 2001; Huang et al., 2001). The phosphorylation of ERK1/2 in the CCRF-CEM cells
treated with 10 μM Cd occurred after 30 min exposure (Iryo et al., 2000). In non-small-cell
lung carcinoma cell line CL3, high concentration of Cd (>80 μM) induced phosphorylation
of ERK1/2 after 6 h of treatment (Chuang et al., 2000). Similarly, in mouse epidermal cells,
Huang et al. (2001) reported that 1 μM Cd induced a sustained activation of ERK1/2
between 20 min and 9 h. Wang and Templeton (1998) reported that ERK1/2 activation in rat
mesangial cells was involved in Cd-induced c-fos mRNA transcription and that inhibition of
ERK1/2 partially attenuated Cd-induced c-fos transcription. Thus different cell lines show
variations in response to Cd-induced activation of ERK1/2 in terms of time-course and
concentration-dependence. It is likely that multiple mechanisms are involved in mediating
this effect and that certain biological responses are cell type specific.
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An important finding in this study was the MDA-MB-231 cells that express only ERβ did
not respond to Cd, ruling out the involvement of this receptor in Cd signaling. GPR30 has
been shown to be involved in rapid E2 signaling events (Filardo et al., 2000; 2002). Since
these cells responded to Cd, GPR30 also appears to interact with Cd.
In conclusion, the results presented here provide evidence that micromolar concentration of
Cd rapidly activate ERK1/2 and AKT in the MCF-7 and SK-BR-3 cells. This process seems
to involve mERα and GPR30. It is plausible that Cd could also bind to other membrane
receptors, upstream kinases or G-protein coupled proteins, which are associated with
specialized cell membrane structural complexes, such as caveolae, causing rapid activation
of downstream kinase cascade (Wong et al. 2002; Chini and Parenti, 2004). Further studies
are needed to elucidate the mechanisms of Cd-induced rapid signaling and to better
understand how Cd interferes with the cell signaling network, affecting normal
physiological function and homeostasis.
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Fig. 1.
Time-course of ERK1/2 activation by Cd and E2 in three different breast cancer cell lines.
(A, B) MCF-7 cells, (C, D) MDA-MB-231 cells, and (E, F) SK-BR-3 cells. The quiescent
cells were treated with 10 μM Cd or 10 nM E2 for up to 60 min. Comparison of temporal
response patterns of Cd- and E2-induced ERK1/2 activation in the three cell lines is shown
in G and H. Data are presented as mean±SD from three independent experiments.
*Significantly higher than the basal level for the respective cells (p < 0.05).
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Fig. 2.
Concentration-response pattern of ERK1/2 activation by Cd in MCF-7 cells. Quiescent
MCF-7 cells were treated with up to 10 μM Cd for 2.5 min. Data are presented as mean±SD
from three independent experiments. *Significantly higher than the basal level (p < 0.05).
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Fig. 3.
Time-course of AKT activation by Cd and E2 in three different breast cancer cell lines. (A,
B) MCF-7 cells, (C, D) MDA-MB-231 cells, and (E, F) SK-BR-3 cells. The quiescent cells
were treated with 10 μM Cd or 10 nM E2 for up to 60 min. Comparison of temporal
response pattern of Cd- and E2-induced AKT activation in the three cell lines is shown in G
and H. Data are presented as mean±SD from three independent experiments. *Significantly
higher than the basal level for the respective cells (p < 0.05).
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Fig. 4.
Time-course of ERα phosphorylation by Cd and E2 in MCF-7 cells. Phosphorylation of
ERα in quiescent cells by: (A, C) 10 μM Cd, and (B) 10 nM E2. Temporal response pattern
of Cd is shown in C. Data are presented as mean±SD from three independent experiments.
*Significantly higher than the basal level (p < 0.05).
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Fig. 5.
Effect of ER antagonist on Cd- and E2-induced activation of ERK1/2 and AKT in MCF-7
cells. The quiescent cells were pretreated with ICI 182,780 (10 μM) or the vehicle (0.1%
ethanol) for 15 min and then treated with either 10 μM Cd or 10 nM E2 in the presence of
the antagonist for 2.5 min. (A, C) Phosphorylation of ERK1/2, and (B, D) phosphorylation
of AKT. Data are presented as mean±SD from three independent experiments.
*Significantly higher than the control cells (p < 0.05). #Significantly lower than the E2 alone
level (p < 0.05).
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Fig. 6.
Effect of suppression of ERα expression on Cd- and E2-induced activation of ERK1/2 in
MCF-7 cells. Forty eight hours after transfection with the non-specific or specific hERα
siRNA, the quiescent cells were treated with either 10 μM Cd or 10 nM E2 for 2.5 min. (A,
C) Phosphorylation of ERK1/2, and (B, D) phosphorylation of AKT. Data are presented as
mean±SD from three independent experiments. *Significantly higher than the respective
control cells (p < 0.05). # Significantly lower than the respective Cd- or E2-treated cells
transfected with non-specific siRNA (p < 0.05).
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